Brokerages Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) PT at $27.71

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been given an average recommendation of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $27.71.

A number of brokerages have recently weighed in on CNTA. Morgan Stanley restated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price objective on the stock.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the sale, the insider now directly owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. This represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Iqbal J. Hussain sold 2,080 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the transaction, the general counsel now owns 105,386 shares of the company’s stock, valued at $1,476,457.86. This trade represents a 1.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 202,353 shares of company stock worth $3,286,478. Company insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its position in Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after buying an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC increased its position in Centessa Pharmaceuticals by 24.3% in the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock worth $58,603,000 after purchasing an additional 684,391 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock worth $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Down 11.6 %

Centessa Pharmaceuticals stock opened at $12.00 on Friday. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09. The company’s fifty day moving average price is $14.07 and its two-hundred day moving average price is $15.74. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -7.84 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04. On average, analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.